Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Compounded products are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease
IDegLira currently carries a black-box warning for risk of thyroid c-cell tumors related to liraglutide, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2
The same day-of-week considerations apply
The STEP-1 follow-up data for Semaglutide showed that participants who discontinued the medication regained approximately two-thirds of their lost weight within one year without significant lifestyle intervention
US$ 21.73
US$ 23.02
US$ 24.13
US$ 21.47
